

# Mari L Demarco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9585766/publications.pdf>

Version: 2024-02-01

60  
papers

2,170  
citations

279798

23  
h-index

233421

45  
g-index

66  
all docs

66  
docs citations

66  
times ranked

2973  
citing authors

#	ARTICLE	IF	CITATIONS
1	From conversion to aggregation: Protofibril formation of the prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2293-2298.	7.1	293
2	Unifying features in protein-folding mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13286-13291.	7.1	225
3	Pauling and Corey's $\beta$ -pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11622-11627.	7.1	133
4	Structural glycobiology: A game of snakes and ladders. Glycobiology, 2008, 18, 426-440.	2.5	130
5	The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 730-743.	2.4	100
6	Extension of the GLYCAM06 biomolecular force field to lipids, lipid bilayers and glycolipids. Molecular Simulation, 2008, 34, 349-364.	2.0	93
7	Molecular Mechanism for Low pH Triggered Misfolding of the Human Prion Protein. Biochemistry, 2007, 46, 3045-3054.	2.5	78
8	Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell, 2022, 185, 1346-1355.e15.	28.9	70
9	Diafiltration MALDI-TOF Mass Spectrometry Method for Culture-Independent Detection and Identification of Pathogens Directly From Urine Specimens. American Journal of Clinical Pathology, 2014, 141, 204-212.	0.7	69
10	Structural Properties of Prion Protein Protofibrils and Fibrils: An Experimental Assessment of Atomic Models. Biochemistry, 2006, 45, 15573-15582.	2.5	67
11	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. Journal of Infectious Diseases, 2022, 225, 1129-1140.	4.0	65
12	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. Npj Vaccines, 2022, 7, 28.	6.0	64
13	Atomic-resolution conformational analysis of the GM3 ganglioside in a lipid bilayer and its implications for ganglioside-protein recognition at membrane surfaces. Glycobiology, 2008, 19, 344-355.	2.5	62
14	Presentation of Membrane-Anchored Glycosphingolipids Determined from Molecular Dynamics Simulations and NMR Paramagnetic Relaxation Rate Enhancement. Journal of the American Chemical Society, 2010, 132, 1334-1338.	13.7	58
15	Biomarker Development for Chronic Obstructive Pulmonary Disease. From Discovery to Clinical Implementation. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1162-1170.	5.6	51
16	Beyond Identification. Clinics in Laboratory Medicine, 2013, 33, 611-628.	1.4	50
17	Local environmental effects on the structure of the prion protein. Comptes Rendus - Biologies, 2005, 328, 847-862.	0.2	45
18	Diffusing and Colliding: The Atomic Level Folding/Unfolding Pathway of a Small Helical Protein. Journal of Molecular Biology, 2004, 341, 1109-1124.	4.2	38

#	ARTICLE	IF	CITATIONS
19	From agonist to antagonist: Structure and dynamics of innate immune glycoprotein MD-2 upon recognition of variably acylated bacterial endotoxins. <i>Molecular Immunology</i> , 2011, 49, 124-133.	2.2	37
20	Biomarker Development in COPD. <i>Chest</i> , 2017, 151, 455-467.	0.8	36
21	Resolution of Spurious Immunonephelometric IgG Subclass Measurement Discrepancies by LC-MS/MS. <i>Clinical Chemistry</i> , 2018, 64, 735-742.	3.2	36
22	Characterization of cell surface prion protein relative to its recombinant analogue: insights from molecular dynamics simulations of diglycosylated, membrane bound human prion protein. <i>Journal of Neurochemistry</i> , 2009, 109, 60-73.	3.9	35
23	People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. <i>Journal of Infectious Diseases</i> , 2023, 227, 838-849.	4.0	31
24	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.8	26
25	Manipulating trypsin digestion conditions to accelerate proteolysis and simplify digestion workflows in development of protein mass spectrometric assays for the clinical laboratory. <i>Clinical Mass Spectrometry</i> , 2017, 6, 1-12.	1.9	25
26	Three-Dimensional Structure of Glycolipids in Biological Membranes. <i>Biochemistry</i> , 2012, 51, 5725-5732.	2.5	19
27	An Intact ACTH LC-MS/MS Assay as an Arbiter of Clinically Discordant Immunoassay Results. <i>Clinical Chemistry</i> , 2019, 65, 1397-1404.	3.2	19
28	Renal Leukocyte Chemotactic Factor 2 (LECT2) Amyloidosis in First Nations People in Northern British Columbia, Canada: A Report of 4 Cases. <i>American Journal of Kidney Diseases</i> , 2014, 64, 790-792.	1.9	18
29	Phenotyping COPD exacerbations using imaging and blood-based biomarkers. <i>International Journal of COPD</i> , 2018, Volume 13, 217-229.	2.3	16
30	Proteoforms and their expanding role in laboratory medicine. <i>Practical Laboratory Medicine</i> , 2022, 28, e00260.	1.3	15
31	C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations. <i>PLoS ONE</i> , 2017, 12, e0174063.	2.5	14
32	The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-7.	1.9	12
33	Sweating the small stuff: Adequacy and accuracy in sweat chloride determination. <i>Clinical Biochemistry</i> , 2015, 48, 443-447.	1.9	11
34	IgG4 plasma cell myeloma without clinical evidence of IgG4-related disease: a report of two cases. <i>Hematology</i> , 2020, 25, 335-340.	1.5	10
35	In Vitro Conversion Assays Diagnostic for Neurodegenerative Proteinopathies. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 142-157.	1.3	9
36	A Streamlined Method for Quantification of Apolipoprotein A1 in Human Plasma by LC-MS/MS. <i>Clinical Chemistry</i> , 2018, 64, 1782-1784.	3.2	8

#	ARTICLE	IF	CITATIONS
37	Detection and characterization of TDP-43 in human cells and tissues by multiple reaction monitoring mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2019, 14, 66-73.	1.9	7
38	&lt;p&gt;Phenotyping and outcomes of hospitalized COPD patients using rapid molecular diagnostics on sputum samples&lt;/p&gt;. <i>International Journal of COPD</i> , 2019, Volume 14, 311-319.	2.3	7
39	An automated mass spectrometric blood test for therapeutic drug monitoring of infliximab. <i>Clinical Mass Spectrometry</i> , 2019, 12, 16-22.	1.9	7
40	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	7
41	MALDI-MS: Emerging roles in pathology and laboratory medicine. <i>Clinical Mass Spectrometry</i> , 2019, 13, 1-4.	1.9	6
42	Identifying Molecular Mechanisms of the Late-Phase Asthmatic Response by Integrating Cellular, Gene, and Metabolite Levels in Blood. <i>Annals of the American Thoracic Society</i> , 2016, 13, S98-S98.	3.2	6
43	An automated clinical mass spectrometric method for identification and quantification of variant and wildâ€type amyloidâ€1â€40 and 1â€42 peptides in CSF. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12036.		5
44	Alpha-1-antitrypsin molecular testing in Canada: A seven year, multi-centre comparison. <i>Clinical Biochemistry</i> , 2020, 81, 27-33.	1.9	5
45	Aptamer-based enrichment of TDP-43 from human cells and tissues with quantification by HPLC-MS/MS. <i>Journal of Neuroscience Methods</i> , 2021, 363, 109344.	2.5	5
46	Proteomic applications in pathology and laboratory medicine: Present state and future prospects. <i>Clinical Biochemistry</i> , 2020, 82, 12-20.	1.9	5
47	Molecular Dynamics Simulations of Membrane- and Protein-Bound Glycolipids Using GLYCAM. <i>Methods in Molecular Biology</i> , 2015, 1273, 379-390.	0.9	4
48	Quantitative Profiling of Synuclein Species: Application to Transgenic Mouse Models of Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 613-621.	2.8	3
49	Grave Clinicopathologic Correlation: A Case of Hyperthyroxinemia. <i>journal of applied laboratory medicine, The</i> , 2016, 1, 310-314.	1.3	3
50	Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2020, 34, 357-359.	1.3	3
51	At the Intersection of Proteomics and Big Data Science. <i>Clinical Chemistry</i> , 2017, 63, 1663-1663.	3.2	2
52	Amplification of Misfolded Prion Proteins in Blood and Cerebrospinal Fluid for Detection of Creutzfeldtâ€Jakob Disease. <i>Clinical Chemistry</i> , 2017, 63, 1671-1673.	3.2	2
53	In IgG4 related disease, elevated IgG2 is an artifact not a biomarker. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, e8.	3.4	2
54	Early increases in anti-SARS-CoV-2 antibody isotypes associated with organ dysfunction and mortality in patients hospitalized with COVID-19. <i>Intensive Care Medicine</i> , 2022, 48, 616-618.	8.2	2

#	ARTICLE	IF	CITATIONS
55	Establishing pre-analytical requirements and maximizing peptide recovery in the analytical phase for mass spectrometric quantification of amyloid- $\beta$ peptides 1-42 and 1-40 in CSF. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 198-206.	2.3	2
56	P1492: Automated Mass Spectrometric Method for Identification and Quantitation of Wild-Type and Familial Variants of Amyloid- $\beta$ Peptides in Cerebrospinal Fluid. <i>Alzheimer's and Dementia</i> , 2016, 12, P477.	0.8	0
57	Ready, Set, Type! Proteomics vs Agglutination for Escherichia coli H Antigen Confirmation. <i>Clinical Chemistry</i> , 2016, 62, 793-795.	3.2	0
58	A Rapidly Deteriorating Patient with Gross Increase in Serum Free Light Chains. <i>Clinical Chemistry</i> , 2019, 65, 1084-1088.	3.2	0
59	P4483: STRUCTURAL CHARACTERIZATION OF TDP43 IN HUMAN CELLS AND BRAIN TISSUE BY MULTIPLE-REACTION-MONITORING MASS SPECTROMETRY. <i>Alzheimer's and Dementia</i> , 2019, 15, P1497.	0.8	0
60	NullCanada: A novel $\alpha$ 1-antitrypsin allele with in cis variants Glu366Lys and Ile100Asn. <i>Clinical Biochemistry</i> , 2020, 79, 23-27.	1.9	0